To strengthen our findings on the targeted and inhibitory effects that strictinin has on ROR1-expressing prostate cancer cells, we wanted to evaluate its potential synergism with docetaxel, which is a standard chemotherapeutic agent that is provided at 75 mg/m2 intravenously (IV) for 1 h every 3 weeks in patients with metastatic prostate cancer [46, 59, 60]. The gene discussed is ROR1; the disease is metastatic prostate carcinoma.